Literature DB >> 10941353

Clinically significant and biopsy-documented renal involvement in primary Sjögren syndrome.

A Goules1, S Masouridi, A G Tzioufas, J P Ioannidis, F N Skopouli, H M Moutsopoulos.   

Abstract

Clinically significant renal involvement in patients with primary Sjögren syndrome (pSS) has been described previously only in isolated case reports. The prevalence and significance of the 2 described syndromes, interstitial nephritis (IN) and glomerulonephritis (GMN), are not well known. In a cohort of 471 patients with pSS who were followed for a mean of 10 years, 20 patients (4.2%) developed overt renal disease. Eighteen patients underwent a percutaneous renal biopsy; 2 patients declined. Ten patients had IN, 8 patients had GMN, and 2 patients presented with both entities. Glomerular histology disclosed changes compatible with membranoproliferative GMN in 5 patients and mesangial proliferative GMN in 4 patients. Patients with IN had a younger disease onset compared with patients with GMN (mean, 36.8 compared with 46.0 yr, p 5 0.063). Patients with GMN had longer disease duration compared with patients with IN (mean, 2.2 compared with 8.0 yr, p 5 0.001). The majority of patients with GMN (80%) had mixed monoclonal cryoglobulinemia IgMk (type II) and lower complement C4 levels. Two patients (both with GMN) developed chronic renal failure requiring hemodialysis. Overall, clinically significant renal involvement is infrequent in pSS. IN occurs early in the disease process, while GMN is a late sequela and may have a less favorable prognosis.

Entities:  

Mesh:

Year:  2000        PMID: 10941353     DOI: 10.1097/00005792-200007000-00005

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  41 in total

1.  Tubulointerstitial immune complex nephritis in a patient with systemic lupus erythematosus: role of peritubular capillaritis with immune complex deposits in the pathogenesis of the tubulointerstitial nephritis.

Authors:  Satoshi Hayakawa; Kimimasa Nakabayashi; Miho Karube; Yoshihiro Arimura; Yoshiro Arimura; Akinori Soejima; Akira Yamada; Yasunori Fujioka
Journal:  Clin Exp Nephrol       Date:  2006-06       Impact factor: 2.801

Review 2.  Conventional therapy of Sjogren's syndrome.

Authors:  Clio P Mavragani; Haralampos M Moutsopoulos
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

3.  End-stage renal failure in adolescence with Sjögren's syndrome autoantibodies SSA and SSB.

Authors:  Sally Johnson; Sally-Anne Hulton; Marie-Anne Brundler; Celia Moss; Aarnoud Huissoon; C Mark Taylor
Journal:  Pediatr Nephrol       Date:  2007-07-17       Impact factor: 3.714

Review 4.  Sjögren's syndrome accompanied with interstitial cystitis: a case report and review of the literature.

Authors:  Dongfeng Liang; Jinshan Lu; Aitao Guo
Journal:  Clin Rheumatol       Date:  2014-01-07       Impact factor: 2.980

5.  Primary Sjögren's syndrome with mesangial proliferative glomerulonephritis and IgA deposits in a child.

Authors:  Seong Kwan Jung; Kyu Hee Park; Hyung Eun Yim; Kee Hwan Yoo; Young Sook Hong; Joo Won Lee; Nam Hee Won
Journal:  Pediatr Nephrol       Date:  2009-11-10       Impact factor: 3.714

6.  Characteristics of primary Sjögren's syndrome patients with IgG4 positive plasma cells infiltration in the labial salivary glands.

Authors:  Chang Liu; Huayong Zhang; Genhong Yao; Yunxia Hu; Jingjing Qi; Yan Wang; Weiwei Chen; Xiaojun Tang; Wenchao Li; Liwei Lu; Luo Gu; Lingyun Sun
Journal:  Clin Rheumatol       Date:  2016-11-18       Impact factor: 2.980

7.  Renal involvement in primary Sjogren's syndrome: a prospective cohort study.

Authors:  Ankit Jain; Bheemanathi Hanuman Srinivas; Dantis Emmanuel; Vikramraj K Jain; Sreejith Parameshwaran; Vir Singh Negi
Journal:  Rheumatol Int       Date:  2018-08-23       Impact factor: 2.631

8.  Treating Sjögren's Syndrome: Insights for the Clinician.

Authors:  Claudio Vitali; Gianluigi Palombi; Pierluigi Cataleta
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-06       Impact factor: 5.346

Review 9.  Sjögren syndrome.

Authors:  Clio P Mavragani; Haralampos M Moutsopoulos
Journal:  CMAJ       Date:  2014-02-24       Impact factor: 8.262

Review 10.  [Renal manifestations of rheumatic diseases].

Authors:  A Schwarting; E Märker-Hermann
Journal:  Z Rheumatol       Date:  2005-02       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.